Clinical Trial Detail

NCT ID NCT01897116
Title A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

melanoma

Therapies

Hydroxychloroquine + Vemurafenib

Age Groups: adult senior

Additional content available in CKB BOOST